Risk of tuberculosis reactivation with tofacitinib (CP-690550)

Mamoudou Maiga*, Shichun Lun, Haidan Guo, Kathryn Winglee, Nicole C. Ammerman, William R. Bishai

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

Individuals with latent tuberculosis infection (LTBI) live with a risk of reactivation, and several treatments for chronic inflammatory conditions are highly associated with such reactivation. A new Janus kinase inhibitor, tofacitinib (CP-690550), has shown promising results for treatment of inflammatory disorders, thus raising concerns of risk of active tuberculosis. Our goal was to characterize the impact of tofacitinib on LTBI using a mouse model of contained tuberculosis. Our data indicate that tofacitinib reduces host containment of Mycobacterium tuberculosis and promotes bacterial replication in the lungs, suggesting tuberculosis reactivation. Tofacitinib may carry a significant risk for LTBI reactivation in humans.

Original languageEnglish (US)
Pages (from-to)1705-1708
Number of pages4
JournalJournal of Infectious Diseases
Volume205
Issue number11
DOIs
StatePublished - Jun 1 2012

Funding

Financial support. This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) (grant numbers AI30036, AI37856 and AI36973) and by the Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Potential conflicts of interest. All authors: No reported conflicts.

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Fingerprint

Dive into the research topics of 'Risk of tuberculosis reactivation with tofacitinib (CP-690550)'. Together they form a unique fingerprint.

Cite this